Star Therapeutics

Star Therapeutics is a biotechnology company founded in 2018 with a mission to develop life-changing therapies for rare diseases. The company's approach involves identifying multiple rare diseases with common biology and discovering novel therapeutics to treat them with a single therapy. It consists of a family of companies, each focusing on a specific area of novel biology and developing first-in-class antibody therapeutics. Electra Therapeutics, the first company within the portfolio, is dedicated to developing therapies targeting signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer. Their latest milestone includes a significant $90.00M Series C investment on 05 September 2023. The investors participating in this round include New Leaf Venture Partners, RA Capital Management, Sofinnova Investments, Qatar Investment Authority, Agent Capital, Catalio Capital Management, Cormorant Asset Management, Cowen Digital, Westlake Village BioPartners, NYBC Ventures. With its innovative approach and focus on addressing unmet needs in the healthcare industry, Star Therapeutics is well-positioned to make a significant impact in the biotechnology sector.